New Zealand - engelsk - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - terazosin hydrochloride dihydrate 1.19mg equivalent to 1 mg terazosin;   - tablet - 1 mg - active: terazosin hydrochloride dihydrate 1.19mg equivalent to 1 mg terazosin   excipient: lactose monohydrate magnesium stearate maize starch purified talc - terazosin tablets are indicated for the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: - prostatectomy is not indicated - patient is not fit for surgery - elective surgery must be postponed (e.g., waiting list) - patient refuses surgical treatment. terazosin is also indicated in the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - terazosin hydrochloride dihydrate 2.38mg equivalent to 2 mg terazosin;   - tablet - 2 mg - active: terazosin hydrochloride dihydrate 2.38mg equivalent to 2 mg terazosin   excipient: lactose monohydrate magnesium stearate maize starch purified talc quinoline yellow - terazosin tablets are indicated for the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: - prostatectomy is not indicated - patient is not fit for surgery - elective surgery must be postponed (e.g., waiting list) - patient refuses surgical treatment. terazosin is also indicated in the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - terazosin hydrochloride dihydrate 5.95mg equivalent to 5 mg terazosin;   - tablet - 5 mg - active: terazosin hydrochloride dihydrate 5.95mg equivalent to 5 mg terazosin   excipient: iron oxide red lactose monohydrate magnesium stearate maize starch purified talc - terazosin tablets are indicated for the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: - prostatectomy is not indicated - patient is not fit for surgery - elective surgery must be postponed (e.g., waiting list) - patient refuses surgical treatment. terazosin is also indicated in the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - terazosin hydrochloride dihydrate 1.19mg equivalent to 1 mg terazosin - tablet - 1 mg - active: terazosin hydrochloride dihydrate 1.19mg equivalent to 1 mg terazosin excipient: lactose magnesium stearate microcrystalline cellulose starch

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - terazosin hydrochloride dihydrate 2.38mg equivalent to terazosin 2 mg - tablet - 2 mg - active: terazosin hydrochloride dihydrate 2.38mg equivalent to terazosin 2 mg excipient: lactose magnesium stearate microcrystalline cellulose quinoline yellow starch sunset yellow aluminium lake - latest regulatory activity

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - terazosin hydrochloride dihydrate 5.95mg equivalent to terazosin 5 mg - tablet - 5 mg - active: terazosin hydrochloride dihydrate 5.95mg equivalent to terazosin 5 mg excipient: ferrosoferric oxide iron oxide red lactose magnesium stearate microcrystalline cellulose starch

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin; terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin - tablet - active: terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin excipient: lactose monohydrate magnesium stearate maize starch purified talc starch active: terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin excipient: lactose monohydrate magnesium stearate maize starch quinoline yellow starch - the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: -prostatectomy is not indicated -patient is not fit for surgery -elective surgery must be postponed (e.g., waiting list) -patient refuses surgical treatment.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

bgp products - terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mgterazosin;  ; terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin; terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg terazosin - tablet - active: terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mgterazosin   excipient: lactose monohydrate magnesium stearate maize starch purified talc starch active: terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin excipient: lactose monohydrate magnesium stearate   maize starch quinoline yellow starch active: terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg terazosin excipient: iron oxide red lactose monohydrate magnesium stearate maize starch purified talc starch

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - terazosin hydrochloride dihydrate 11.87mg equivalent to 10 mg terazosin - tablet - 10 mg - active: terazosin hydrochloride dihydrate 11.87mg equivalent to 10 mg terazosin excipient: indigo carmine lactose monohydrate magnesium stearate maize starch purified talc

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin - tablet - 1 mg - active: terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin excipient: lactose monohydrate magnesium stearate maize starch purified talc